SCHEMBL30409293

SCHEMBL30409293

O=C1NC2(CCO1)CN(C(=O)N1CCC3(CC1)CN(Cc1ccc(C(F)(F)F)cc1F)C3)C2

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.42
▸ MGLL Q99685 4/20 0.41
▸ USP2 O75604 7/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GPR183 P32249 2/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ ENPP2 Q13822 3/20 0.39
▸ ATXN2 Q99700 3/20 0.39
▸ ABHD6 Q9BV23 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25146080 0.92 MGLL (0.47) FAAHMGLLUSP2HPGDALDH1A1
SCHEMBL25146247 0.87 FAAH (0.44) FAAHMGLLUSP2HPGDALDH1A1
SCHEMBL25146318 0.86 MGLL (0.46) FAAHMGLLGPR183ENPP2ATXN2
SCHEMBL30409855 0.86 MGLL (0.46) FAAHMGLLGPR183ENPP2ATXN2
SCHEMBL25145621 0.85 FAAH (0.41) FAAHMGLLUSP2HPGDALDH1A1
SCHEMBL25146079 0.84 FAAH (0.43) FAAHUSP2HPGDALDH1A1TSHR
SCHEMBL25146284 0.80 ENPP2 (0.42) FAAHMGLLUSP2ALDH1A1TSHR
SCHEMBL30409906 0.80 MGLL (0.41) FAAHMGLLUSP2HPGDALDH1A1
SCHEMBL25146103 0.80 CACNA1B (0.41) MGLLALDH1A1TSHRCYP2C9
SCHEMBL25146037 0.78 MGLL (0.45) FAAHMGLLCYP2D6ABHD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416154-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-08-21 — — EP claimed
CN-118103374-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2024-05-28 — — CN claimed
WO-2023062049-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO claimed
US-20240383904-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-21 — — US disclosed
EP-4416154-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-08-21 — — EP disclosed
CN-118103374-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2024-05-28 — — CN disclosed
WO-2023062049-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383904-A1 HETEROCYCLIC COMPOUNDS MAGI3, MAG, MAGT1 FAAH 54/4885MGLL 5/4885USP2 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback